Company intelligence / Profile preview

CTMA

Asnières-sur-Seine / Paris area, Île-de-France, Francetongji.ctma.net ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

CTMA developed the CT-SCOUT™ web platform to accelerate and optimize patient recruitment in clinical trials. The technology enables real-time identification of eligible patients by healthcare professionals, improving early recognition and enrollment rates. As of its acquisition, the platform had been used to support over 5,000 studies across more than 20,000 sites globally.[1][2] In early 2022, it expanded into rheumatology indications.[3]

Therapeutic areas: RheumatologyImmunology
Industry: Biomedical IT and Biomedical Data Platforms

Beyond the preview

Go deeper on CTMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTMA.

Explore the full profile